Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.
We have examined the immunoregulatory effect of local and continuous secretion of interleukin 7 (IL-7) from murine glioma cells (203-glioma) engineered by murine IL-7 gene transfection. Secretion of IL-7 from glioma cells did not result in morphology or growth rate changes but did reduce tumorigenicity in vivo in proportion to the amount of IL-7 produced. This reduction in tumorigenicity could be reversed in a dose-dependent fashion by injection of anti-IL-7 neutralizing monoclonal antibody at the tumor site. Mice immunized with IL-7-producing glioma cells showed a specific immune response to 203-glioma but not to two other syngeneic cell lines (B-16, a melanoma, and YM-12, a fibrosarcoma). IL-7-producing glioma cells were not rejected in mice depleted of CD8+ cells but were rejected in mice depleted of CD4+ or NK1.1+ cells. These results suggest that CD8+ T cells may play an important role in tumor rejection.
Aoki
T
T
Department of Neurosurgery, Faculty of Medicine, Kyoto University, Japan.
Tashiro
K
K
Miyatake
S
S
Kinashi
T
T
Nakano
T
T
Oda
Y
Y
Kikuchi
H
H
Honjo
T
T
D000818:Animals; D016827:CD8 Antigens / Q000032:analysis; D005910:Glioma / Q000276:immunology*; D006084:Graft Rejection; D007111:Immunity, Cellular; D015851:Interleukin-7 / Q000502:physiology*; D007694:Killer Cells, Natural / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000473:pathology; D011994:Recombinant Proteins; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014162:Transfection; D014407:Tumor Cells, Cultured
D016827:CD8 Antigens; D015851:Interleukin-7; D011994:Recombinant Proteins